Roche medical director could face GMC if the company withheld relevant data on oseltamivir

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8408 (Published 11 December 2012)
Cite this as: BMJ 2012;345:e8408

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. 1BMJ

The chairman of the UK National Institute for Health and Clinical Excellence has said that if Roche were found to have withheld relevant data on its drug oseltamivir (Tamiflu) the company’s medical director at the time of the submission to NICE could be reported to the General Medical Council.

Michael Rawlins was responding to a letter from the BMJ’s editor in chief, Fiona Godlee, in which she asked NICE to withdraw its guidance on oseltamivir until it “has received and reviewed the full clinical trial data.” The request was the latest move in the BMJ’s open data campaign (bmj.com/tamiflu), which aims to persuade Roche to honour the promise it made almost three years ago to make key trial data on oseltamivir available for independent scrutiny.

In her letter Godlee said that …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL